HDAC6 inhibitor for ALS

Researchers tested EKZ-438, a highly selective HDAC6 inhibitor that reaches the brain and is well absorbed. In Amyotrophic lateral sclerosis (ALS) models, it helped clear misfolded proteins, improved neuron survival, and boosted transport inside cells. In mice and human neuron models of ALS, it reduced disease features and inflammation, suggesting a path toward slowing ALS in people, though it remains early preclinical work.